12 reports

  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition
  • 8.1 REFERENCES

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This...

  • Cancer
  • Cancer Immunotherapy
  • Lung Cancer
  • Therapy
  • Gilead Sciences, Inc.

Pancreatic cancer

4385 5000 3900
  • Forecast: Pancreatic Cancer
  • Pipeline: Pancreatic Cancer

The prognosis of patients with pancreatic cancer remains poor; however, this clinical need will drive future market expansion and the development of several targeted therapies. This report addresses the following questions: -What are the current treatment options for patients with pancreatic cancer in each therapeutic...

  • Cancer
  • Obesity
  • Pancreatic Cancer
  • Therapy
  • Gilead Sciences, Inc.
  • Global Monoclonal Antibody Sterile Injectables Market
  • Scope of the Report - Sterile Injectables Market

Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Sterile Injectables Market by Molecule Type (Biologic, Small Molecule), Drug Type (Monoclonal Antibody,...

  • Cancer
  • Cardiovascular Disease
  • Endocrine Disease
  • Baxter International Inc.
  • Gilead Sciences, Inc.

HOWEVER, SOME OF THE DRUGS ARE USED FOR ONE OR MORE TYPES OF CANCERS.

  • Cancer
  • World
  • Company Financials
  • Forecast
  • Gilead Sciences, Inc.
  • Market Access of Immuno-oncology Therapies in the 5EU Immuno-oncology Therapies Marketed in the 5EU

RESEARCH BEATING CANCER: AMBITION AND ACTION (2016) [##] NATIONAL CANCER STRATEGY 2017-2026 [##] ##.

  • Cancer
  • Oncology
  • Pharmaceutical
  • Southern Europe
  • Gilead Sciences, Inc.
  • DEVELOPMENT OVERVIEW
  • PRODUCT PROFILE

Clinical Cancer Research, ##(##), ##-## < PMID> ##< / PMID>.

  • Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Gilead Sciences, Inc.
  • ENDPOINT RESULTS FOR DRUGS IN FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA

James Cancer Hos- pital and Richard J.

  • Cancer
  • Lymphoma
  • Therapy
  • Gilead Sciences, Inc.
  • Roche Group

CANCER; ##(##): ##- ##.

  • Cancer
  • Epidemiology
  • Lymphoma
  • Therapy
  • Gilead Sciences, Inc.
  • CANCER GENETICS ENTERS INTO AGREEMENT WITH GILEAD SCIENCES TO PROVIDE CLINICAL TRIAL SERVICES
  • KITE PHARMA ENTERS INTO R&D AGREEMENT WITH NATIONAL CANCER INSTITUTE

Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company.It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The...

  • Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Gilead Sciences, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018
  • INTRODUCTION

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Cancer
  • Dermatological Treatment
  • Hospital
  • Therapy
  • Gilead Sciences, Inc.
  • Products under Development by Companies, H1 2018

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Cancer
  • Hospital
  • World
  • Product Initiative
  • Gilead Sciences, Inc.
  • eleclazine
  • Gilead Sciences, Inc. - Dormant Projects

Tesmilifene (YMB##) was under development for the treatment of metastatic or recurrent breast cancer, hepatic cancer, hormone-refractory prostate cancer and gastric cancer.

  • Cancer
  • Hepatitis Treatment
  • Research And Development
  • Therapy
  • Gilead Sciences, Inc.